To understand the relationship between tumor cell PD-L1 positivity and other lung cancer tumor driver gene alterations, especially those with available targeted therapeutic agents, we profiled EGFR, KRAS, MET, ALK and ROS1 gene abnormalities in the same cohort, dependent on tumor sample availability (Table 2 and Figure 3). The gene discussed is MET; the disease is lung carcinoma.